<DOC>
	<DOCNO>NCT02615496</DOCNO>
	<brief_summary>The study observational , cross-sectional study knowledge , understanding , self-reported behavior among sample physician patient recent aflibercept experience total five European country .</brief_summary>
	<brief_title>Evaluation Physician Patient Knowledge Safety Safe Use Information Aflibercept</brief_title>
	<detailed_description />
	<mesh_term>Macular Degeneration</mesh_term>
	<criteria>Physicians eligibility : Licensed practice ophthalmologist Prescribed administer aflibercept least one patient past 6 month Patients eligibility : Patient administer aflibercept least within last 6 month indication return subsequent visit . Patient age 18 year old . Patient able understand sign consent form patient questionnaire . Patient understand native language country study conduct . Patient participate clinical trial treatment aflibercept indication ( e.g. , wAMD , CRVO , DME ) past 12 month .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Health Care Surveys</keyword>
	<keyword>Vascular Endothelial Growth Factor</keyword>
</DOC>